# A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366

> **NCT03378648** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 118 (actual)

## Conditions studied

- Asthma
- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** CHF6366
- **DRUG:** Placebo CHF6366
- **DRUG:** umeclidinium bromide and vilanterol trifenatate

## Key facts

- **NCT ID:** NCT03378648
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-28
- **Primary completion:** 2019-04-16
- **Final completion:** 2019-04-16
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2020-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03378648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03378648, "A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03378648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*